the benefits of glp-1 drugs beyond obesity expanding role receptor agonists: a narrative review of current evidence and future directions GLP-1 agonists and changes in

Diabetes Care 44, 14621471

Given the observed increased risk of colorectal cancer among patients receiving GLP-1 receptor agonists, clinicians should approach long-term prescribing of these agents with careful consideration, particularly in individuals with additional risk factors for colorectal cancer, such as a family history, obesity, inflammatory bowel disease, or long-standing type 2 diabetes

The gut microbiota and host health: a new clinical frontier

Liraglutide has demonstrated to determine significant weight loss, reduce pre-diabetes rate and improve obesity-related risk factors independently from the presence of T2DM [38,40,41,50,56,57,58,59]

Avogaro, S

When will my medication be delivered after an online consultation